The effect of arsenic on urethan-induced adenoma formation in Swiss mice.
Female Swiss mice were exposed to sodium arsenite or sodium aresenate in the drinking water for 15 weeks at concentrations ranging from 0 to 100 micrograms/mL arsenic content. After three weeks of the 15 week exposure period, the mice were administered urethan (1.5 mg/g) intraperitoneally. Pulmonary adenoma formation was evaluated 12 weeks later. Arsenic exposure produced a protective effect with respect to tumor development. Both forms of arsenic reduced the size and number of pulmonary adenomas observed per mouse. In addition, urethan-induced sleeping times which reflect the rate of urethan metabolism or excretion remained unchanged. This suggests that arsenic exposure does not alter urethan excretion and is not a factor influencing subsequent adenoma formation of these levels of exposure.
D000236:Adenoma / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D001149:Arsenates / Q000378:metabolism / Q000494:pharmacology*; D001151:Arsenic / Q000378:metabolism / Q000494:pharmacology*; D018053:Arsenites; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D004326:Drinking / Q000187:drug effects; D005260:Female; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008175:Lung Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D017670:Sodium Compounds; D014520:Urethane
D001149:Arsenates; D018053:Arsenites; D017670:Sodium Compounds; D014520:Urethane; C017947:sodium arsenite; C009277:sodium arsenate; D001151:Arsenic